서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 16 of 16

Issue DateTitle / Author(s) / CitationFileAltmetrics
2005-12
Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer
DOI
2007-07
Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea-Japan collaborative study group trial
DOI
2007-09
Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer
view file
2008-12
The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines
DOI
2010-05
Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer
DOI
2013-04
Tumor suppressor p16(INK4a) inhibits cancer cell growth by downregulating eEF1A2 through a direct interaction
DOI
2013-06
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
DOI
2013-12
Effects of pigment epithelium derived factor (PEDF) on malignant peripheral nerve sheath tumours (MPNSTs)
DOI
2014-08
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

Kang, Y-K; Rha, S. Y.; Tassone, P.; Barriuso, J.; Yu, R.; Szado, T.; Garg, A.; Bang, Y-J

British Journal of Cancer, Vol.111 No.4, pp.660-666

DOI
2014-08
Single-Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Pathway and Outcomes of Patients Treated with First-Line Cytotoxic Chemotherapy Combined with Bevacizumab for Advanced Colorectal Cancer
DOI
2015-01
ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy
DOI
2015-11
Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer
DOI
2016-08
Dual CD44 and folate receptor-targeted nanoparticles for cancer diagnosis and anticancer drug delivery
DOI
2017-01
Detrimental Effects of Higher Body Mass Index and Smoking Habits on Menstrual Cycles in Korean Women
DOI
2017-03
Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer
DOI
2023-05
High-throughput organo-on-pillar (high-TOP) array system for three-dimensional ex vivo drug testing
DOI
1